- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07651345
Trial to Evaluate the Impact of Various Pragmatic Interventions to Increase Mammography Uptake Among Defaulted Repeat Screeners in Singapore (REMIND1)
Randomized Controlled Trials to Evaluate Outreach Strategies for Increasing Mammogram Uptake in Singaporean Women Who Are Defaulted Repeat Screeners
Breast cancer is the most common cancer among women in Singapore, accounting for nearly 30% of all female cancers. While regular biennial mammography can reduce mortality, screening rates in Singapore remain low at 34.7%; well below the 70% threshold required for population-level impact. Despite a national screening program in place since 2002, uptake continues to be hindered by psychological, cultural, and logistical barriers. Although various studies have explored different behavioural interventions to boost mammogram uptake; ranging from reminders (traditional mailers, phone calls, text messages) and education to financial incentives, their effectiveness varies by population and context. Furthermore, few large-scale, prospective studies have been conducted locally. Prior research in Singapore is either outdated or limited in scope, and there is a particular lack of rigorous trials evaluating behavioral interventions tailored to women who have defaulted on screening, who faces distinct psychological and behavioral barriers; ranging from low perceived risk and fear, to false reassurance from prior normal results or lack of reminders, or had bad experience (procedural pain or prior false positive results) during last mammogram. Engaging these women is critical, yet challenging, and failure to do so undermines efforts to achieve broad population coverage.
The REMIND Study addresses this critical gap by evaluating five pragmatic and scalable outreach strategies to increase mammogram uptake among women who had their last screening more than 2 years ago and are currently overdue. Through a large, randomized controlled trial, the study will generate much-needed local evidence on what works to reengage these women. Findings will directly inform national screening policies and the design of future outreach efforts tailored to Singapore's diverse population.
연구 개요
상태
상세 설명
The REMIND Study is a five-arm randomized controlled trial (RCT) designed to evaluate the effectiveness of a few behavioral interventions to increase mammogram uptake among women aged 50-69 years who have defaulted on mammogram screening. The study's specific aim is to identify effective, affordable, and scalable behavioral interventions that can be implemented in Singapore's general population to improve participation in surveillance mammography. This is a minimal-risk, population-based study that does not require participant visits or in-person interaction, except for a subset involved in a follow-up telephone survey.
Eligibility Criteria: Singaporean women, aged 50-69, who are eligible for free biennial mammograms, with no history of prior breast cancer, have had at least one mammogram before, but not screened in the past 2 years will be will be identified using the NUH electronic medical health records system (EPIC). We will restrict the selection to NUHS patients who are registered users of the NUHS App. To further select/narrow down the eligible participants app activity or last log in date will be used. Patients who signed up the NUHS App have all consented to receive push notifications on research studies. There are over 600,000 registered users of NUHS App. The required 12,750 patients for the study will be randomly selected from these eligible patients.
Randomization and Intervention Arms: A total of 12,750 eligible women will be randomly assigned in equal proportions (n=2,550 per arm) to one of the following five groups:
- no intervention (control);
- standard mailed reminder (MR);
- MR plus a second MR sent four weeks later;
- MR with a pre-scheduled mammogram appointment; and
- MR containing behavioral nudge messaging (e.g., social norm or gain or loss framing techniques).
Randomization will be computer-generated. NOTE: Arm 1 represents the current standard practice at NUHS, where patients are not routinely invited or reminded to attend mammogram screenings.
Women in intervention arms 2-5 will receive their respective outreach materials by post (personalized mailers on NCIS letter head) as well as push notifications via the NUHS app. 5-7 days after the mailers are sent, 1st batch of PN will be sent. Up to three batches of PN will be sent to all participants in Arms 2-5, 3 weeks apart. The push notifications will either be linked to a microcontent landing page or a webpage on NCIS website. The content of the mailers and landing page/ webpage will be the same explaining the importance of regular mammography, tailored messages according to each intervention type, and relevant booking instructions or appointment details. These materials have been designed to reflect evidence-based behavioral science strategies and were co-developed in consultation with clinicians, behavioural science experts, and community stakeholders. Participants in the control arm (Arm 1) will not receive any intervention.
This is a minimal-risk study. There are no in-person visits, clinical procedures, or additional tests required. Participation primarily involves receiving reminders. Women may choose to opt out of the study at any time.
Outcome measurement: All data on mammogram completion will be obtained from existing sources such as electronic medical records and the national screening registry. The primary outcome is mammogram uptake within four months of the first intervention (date of sending the mailer/ push notification, which ever is later). In addition to the primary time point, mammogram uptake data may also be extracted at the 6-month and 12-month marks following the intervention. These extended follow-up points will allow for the assessment of any delayed uptake, which may help to understand the longer-term impact of the interventions. No new clinical data will be generated from participants.
NOTE: To avoid a huge surge in calls to the appointment booking hotline number, mailers will be sent in a staggered manner over 4-12 weeks. Hence, the collection of mammogram completion data will also be staggered and will be 4 months from the day of sending the mailers/PNs which ever is the later. Similarly, for the participants in Arm 4 (mailer reminder with pre-scheduled appointment), the mailers/PN will be sent out 4-6 weeks prior to the appointment date and the mammogram completion date will be calculated four months from the date the mailer/PN was sent.
Post-trial telephone survey: In addition post-trial, a subset of participants from Arms 2-5, will be randomly selected to participate in a telephone survey aimed at understanding motivations, barriers, and perceptions related to the interventions and screening. Participants will be randomly selected and contacted until a total of up to 70 participants in each arm responds and takes part in the survey. About 3-8 weeks post trial, the participants will be contacted via phone, and verbal consent will be obtained prior to initiating the survey. They will be informed that the survey will take about 5-10 minutes, their participation is voluntary, they may skip any question or withdraw at any time, and their responses will remain confidential. Trained research staff will be performing the telephone survey.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Singapore, 싱가포르
- National University Hospital Singapore
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Singaporean citizen
- Age 50-69
- Registered as a patient at the National University Hospital
- Registered and active user of NUHS App
- Signed up with Healthier SG with a primary care provider within the NUHS Primary Care Network
- Must be defaulted repeat screeners : Must have done one prior mammogram screening but not in the past 2 years
Exclusion Criteria:
- Diagnosis of breast cancer in EPIC
- Mammogram done in the past 24 months in EPIC
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 상영
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm 5: 강화된 메시징이 포함된 우편 리마인더
향상된 메시징이 포함된 우편 알림을 수신합니다
|
Receives one mailed reminder with enhanced messaging motivating recipient to undergo screening
|
|
간섭 없음: Control Arm (Arm 1)
Does not receive any reminder to go for mammogram
|
|
|
실험적: Arm 2: One mailed reminder
Receives a single mail reminder
|
유방암에 관한 기본 정보와 유방촬영술 예약 방법에 대한 안내가 포함된 우편 리마인더를 받습니다
|
|
실험적: Arm 3: Two mailed reminders
Receives two mail reminders, 4 weeks apart
|
Receives a mailed reminder + follow-up mailed reminder, 4 weeks after the first
|
|
실험적: Arm 4: Mailed Reminder with Prescheduled Appointment
Receives a mailed reminder with prescheduled appointment
|
사전 예약된 약속과 함께 우편으로 한 번의 리마인더를 수신하며, 약속 변경 방법에 대한 안내가 포함됩니다.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Comparison of proportion of participants completing surveillance mammography within 4 months after intervention assignment between interventional arms (2-5) and control arm (Arm 1)
기간: 4 months from the time participants receive the intervention/reminder
|
The proportion of women who undergo surveillance mammography within 4 months of receiving the study intervention/reminder will be compared between Arm 1 (control) and Arms 2-5.
Mammogram completion will be confirmed through electronic medical records.
Results will be reported as the percentage of participants completing mammography in each study arm.
Unit of Measure: Percentage of participants (%)
|
4 months from the time participants receive the intervention/reminder
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
시험 후 6개월 및 12개월 시점의 유방촬영 검사 참여율
기간: 참가자가 첫 번째 우편 알림을 받은 시점으로부터 6개월 및 12개월
|
초기 연구 후 6개월 및 12개월 경과 시점의 유방촬영 완료율 비교
|
참가자가 첫 번째 우편 알림을 받은 시점으로부터 6개월 및 12개월
|
|
Association between participant characteristics and completion of surveillance mammography within 4 months
기간: 4 months from the time participants receive the intervention/reminder
|
Multivariable logistic regression will be used to evaluate the association between participant characteristics and mammogram completion within 4 months after intervention.
Covariates include age, race, housing type, and duration overdue for screening.
Results will be reported as adjusted odds ratios with 95% confidence intervals.
|
4 months from the time participants receive the intervention/reminder
|
|
Post-trial telephone survey
기간: 1-2 months post-trial
|
A post-trial telephone survey of about 280 participants will gather insights into their response to the interventions.
The study aims to provide actionable insights into effective, scalable interventions to improve mammography uptake and reduce breast cancer mortality in Singapore.
|
1-2 months post-trial
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
유방암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)완전한피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
SB Istanbul Education and Research Hospital아직 모집하지 않음Thryoid cancer | parathyrıoid 선종
-
Jonsson Comprehensive Cancer CenterNovartis Pharmaceuticals모병전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center모병전립선 선암종 | 2기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Society for Endocrinology초대로 등록
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
Arm 2: 우편물 한 통의 알림에 대한 임상 시험
-
Uskudar University모병
-
ISPA - Instituto Universitario de Ciencias Psicologicas...아직 모집하지 않음
-
Centre Hospitalier St Anne아직 모집하지 않음
-
Children's Hospital of PhiladelphiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Boston Children... 그리고 다른 협력자들완전한
-
National University Hospital, Singapore초대로 등록이 연구에서는 싱가포르 여성의 조기 유방암 발견을 위한 유방조영술 감시 활용을 늘리기 위한 중재를 평가합니다.싱가포르
-
Fatih Sultan Mehmet Training and Research Hospital아직 모집하지 않음